Company / Capital Expenditures
ORAMED PHARMACEUTICALS INC. Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$18.0K
FY2025
5-year range
$18.0K / $496.0K
FY2021-FY2025
Trend
-92.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures has fluctuated over the past 10 years, ranging from $1,000 in FY2017 to $496,000 in FY2023.
Based on SEC 10-K filings.
$18,000 in FY2025 with a 5-year CAGR of +3.7%.
Declined from $496,000 to $18,000 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -63.7%
- 5-Year CAGR
- +3.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +3.7%, indicating consistent growth.
- In FY2025, capital expenditures decreased 92.9% year-over-year.
- Peak capital expenditures was recorded in FY2023.
- Lowest capital expenditures in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score 0.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $18.0K | -92.9% |
| FY2024 | $254.0K | -48.8% |
| FY2023 | $496.0K | +32.3% |
| FY2022 | $375.0K | +357.3% |
| FY2021 | $82.0K | +446.7% |
| FY2020 | $15.0K | +114.3% |
| FY2019 | $7.0K | -22.2% |
| FY2018 | $9.0K | +800.0% |
| FY2017 | $1.0K | -92.9% |
| FY2016 | $14.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026